Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Sami L Bahna
The food allergy (FA) entity went through a long difficult road which led to much delay in its recognition. After long periods of denial and misdiagnosis, it attained its current designation as food hypersensitivity or allergy. This review will briefly address the evolution of the FA entity from the early BC era until our 21st century and highlight the milestones in the main aspects of diagnosis, treatment, prevention, and research. A great recognition of the allergy specialty was gained by the discovery of its main mediator -immunoglobulin E in 1967 - which also helped in classifying FA into IgE-mediated (immediate-type) and non-IgE-mediated...
May 2024: World Allergy Organization Journal
#2
REVIEW
Carmen Riggioni, Teresa Oton, Loreto Carmona, George Du Toit, Isabel Skypala, Alexandra F Santos
UNLABELLED: Food allergy (FA) is a potentially life-threatening chronic condition that is becoming an increasing public health problem worldwide. This systematic review (SR) was carried out to inform the development of clinical recommendations on the treatment of IgE-mediated FA with biologics and/or IT for the update of the EAACI guidelines. A SR of randomized-controlled trials or quasi-controlled trials was carried out. Studies were identified via comprehensive search strategies in Medline, Embase, and Cochrane Library, up to April 2022...
May 15, 2024: Allergy
#3
REVIEW
Julia Kuźniar, Patrycja Kozubek, Krzysztof Gomułka
Food allergy (FA) has become a common global public health issue, with a growing prevalence in the modern world and a significant impact on the lives of patients, their families, and caregivers. It affects every area of life and is associated with elevated costs. Food allergy is an adverse immune reaction that occurs in response to a given food. The symptoms vary from mild to severe and can lead to anaphylaxis. This is why it is important to focus on the factors influencing the occurrence of food allergies, specific diagnostic methods, effective therapies, and especially prevention...
April 27, 2024: Nutrients
#4
REVIEW
Maria Pasioti, Paraskevi Xepapadaki, Alexander G Mathioudakis, John Lakoumentas, Elvira Efstathiou, Nikolaos G Papadopoulos
Tree nut allergy is a lifelong and potentially life-threatening condition. The standard of care is strictly avoiding the culprit nut and treating accidental reactions symptomatically. To evaluate potential therapeutic options for desensitizing patients with IgE-mediated tree nut allergy, we systematically searched three bibliographic databases for studies published until January 2024. We looked for active treatments of IgE-mediated allergy to tree nuts (walnut, hazelnut, pistachio, cashew, almond, pecan, macadamia nut, and brazil nut)...
May 2024: Pediatric Allergy and Immunology
#5
Shifaa Alkotob, Philippe Bégin, Aikaterini Anagnostou
No abstract text is available yet for this article.
April 27, 2024: Allergy
#6
EDITORIAL
Alessandro Fiocchi, Motohiro Ebisawa
No abstract text is available yet for this article.
June 1, 2024: Current Opinion in Allergy and Clinical Immunology
#7
REVIEW
Nikhil Chowdary Peddi, Sudheer Kumar Muppalla, Himabindu Sreenivasulu, Sravya Vuppalapati, Myna Komuravelli, Rahul Navab
Food allergy is a major health concern worldwide, encompassing both immunologic and non-immunologic reactions. This review thoroughly examines the pathophysiology, clinical manifestations, and treatment options for various types of food allergies. Immunologic food allergies, including IgE-mediated reactions such as oral allergy syndrome and systemic anaphylaxis, pose various diagnostic and management challenges. Non-IgE-mediated reactions such as food protein-induced enterocolitis syndrome, dermatitis herpetiformis, and proctocolitis necessitate individualized patient care...
March 2024: Curēus
#8
REVIEW
Simone Foti Randazzese, Ilenia Panasiti, Lucia Caminiti, Francesco Catamerò, Massimo Landi, Maria De Filippo, Martina Votto, Roberta Olcese, Filippo Favuzza, Mattia Giovannini, Salvatore Barberi
Peanut allergy affects about 1%-3% of the pediatric population in the world, with an important increase in the last decades. Nowadays, international guidelines recommend the early introduction of peanuts in the infant diet, with poor information about the quantity and the frequency of the intake. Allergen immunotherapy may represent the only therapeutic strategy able to modify the natural history of peanut allergy. In particular, oral immunotherapy showed the most promising results in terms of efficacy, but with significant rates of adverse reactions, mostly gastrointestinal...
April 2024: Pediatric Allergy and Immunology
#9
REVIEW
Thomas B Casale, Alessandro Fiocchi, Matthew Greenhawt
The recent approval of omalizumab for the treatment of IgE-mediated food allergy is an important step forward for the millions of food allergy patients in the US. Through the depletion of circulating IgE and the subsequent reduction of FCεR1 on key effector cells, patients increase their tolerance to food allergens. However, omalizumab does not permit patients to eat foods that they are allergic to with impunity. Rather, it protects them from most accidental exposures. In addition, omalizumab does not cure food allergy and has not demonstrated true immunomodulation...
April 8, 2024: Journal of Allergy and Clinical Immunology
#10
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2024: Medical Letter on Drugs and Therapeutics
#11
JOURNAL ARTICLE
Jackson P Schuetz, Brent Anderson, Sayantani B Sindher
PURPOSE OF REVIEW: This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options. RECENT FINDINGS: Antiimmunoglobulin E mAbs, exemplified by omalizumab, demonstrate efficacy in desensitization and safety improvement during multiallergen OIT...
March 29, 2024: Current Opinion in Allergy and Clinical Immunology
#12
JOURNAL ARTICLE
Giulio Dinardo, Arianna Cafarotti, Vincenzo Fierro, Maria Cristina Artesani, Cristiana Indolfi, Michele Miraglia Del Giudice, Alessandro Fiocchi
PURPOSE OF REVIEW: This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities. RECENT FINDINGS: This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management...
March 28, 2024: Current Opinion in Allergy and Clinical Immunology
#13
JOURNAL ARTICLE
Ana María Agar Muñoz, César Alberto Galván Calle
Despite promising advancements in oral immunotherapy for food allergies, medical implementation faces limitations. Non-specific treatment options based on inhibiting the type 2 inflammatory pathway, including monoclonal antibodies, are under investigation. TNX-901 and omalizumab have demonstrated increased reaction thresholds, reducing adverse events in peanut-allergic patients. Dupilumab, blocking the IL-4 receptor, shows positive results in both food allergies and eosinophilic esophagitis. Antibodies against alarmins and anti-IL-5, such as etokimab and mepolizumab, have proven efficacy in preclinical studies and clinical trials...
December 31, 2023: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
#14
JOURNAL ARTICLE
Ignacio Javier Ansotegui Zubeldia, Alessandro Fiocchi
Food allergy is a common chronic disorder that affects infants, children, adolescents, and adults. The prevalence of food allergy has increased in recent decades throughout the world, not limited to Western countries. Since there is no treatment, this focuses on avoiding allergens, in addition to educating patients and caregivers in the emergency treatment of acute reactions, for example: application of epinephrine. Studies suggest that accidental reactions occur in about 45% of children with food allergies each year, although most reactions are mild or moderate in severity...
December 31, 2023: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
#15
JOURNAL ARTICLE
Hugh A Sampson, J Andrew Bird, David Fleischer, Wayne G Shreffler, Jonathan Spergel
No abstract text is available yet for this article.
March 11, 2024: Annals of Allergy, Asthma & Immunology
#16
EDITORIAL
Ann Robinson
No abstract text is available yet for this article.
March 7, 2024: BMJ: British Medical Journal
#17
JOURNAL ARTICLE
Zhirong Du, Zixi Wang, Weixun Zhou, Jia Yin, Yuxiang Zhi
BACKGROUND: Eosinophilic gastritis (EoG) has rarely been reported in conjunction with gluten-sensitive enteropathy (GSE). When this does occur, patients typically present with gastrointestinal symptoms. To our knowledge, hypoproteinemia has not been reported as the primary manifestation. Anti-IgE therapy, such as omalizumab, lowers eosinophil counts in the blood, lungs, and gut. Its efficiency in treating active EoG remain unknown. CASE PRESENTATION: We report a 33-month-old boy with a history of food allergy and atopic dermatitis who developed recurrent edema, hypoproteinemia, and eosinophilia at the age of 14 months...
March 5, 2024: Allergy, Asthma, and Clinical Immunology
#18
JOURNAL ARTICLE
Robert A Wood, Alkis Togias, Scott H Sicherer, Wayne G Shreffler, Edwin H Kim, Stacie M Jones, Donald Y M Leung, Brian P Vickery, J Andrew Bird, Jonathan M Spergel, Ahmar Iqbal, Julie Olsson, Monica Ligueros-Saylan, Alkaz Uddin, Agustin Calatroni, Charmaine Marquis Huckabee, Nicole H Rogers, Nancy Yovetich, Jennifer Dantzer, Kim Mudd, Julie Wang, Marion Groetch, David Pyle, Corinne A Keet, Michael Kulis, Sayantani B Sindher, Andrew Long, Amy M Scurlock, Bruce J Lanser, Tricia Lee, Christopher Parrish, Terri Brown-Whitehorn, Amanda K Rudman Spergel, Maria Veri, Sanaz Daneshfar Hamrah, Erica Brittain, Julian Poyser, Lisa M Wheatley, R Sharon Chinthrajah
BACKGROUND: Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. METHODS: In this trial, we assessed whether omalizumab, a monoclonal anti-IgE antibody, would be effective and safe as monotherapy in patients with multiple food allergies. Persons 1 to 55 years of age who were allergic to peanuts and at least two other trial-specified foods (cashew, milk, egg, walnut, wheat, and hazelnut) were screened...
February 25, 2024: New England Journal of Medicine
#19
JOURNAL ARTICLE
Young-Min Ye, Jung-Won Park, Sae-Hoon Kim, You Sook Cho, Sook Young Lee, Sae Young Lee, Sujin Sim, Eunji Song, Bomin Kim, Jieon Lee, Su Kyung Kim, Myoung Ho Jang, Hae-Sim Park
BACKGROUND: YH35324, a long-acting IgETrap-Fc fusion protein, is a novel therapeutic agent for immunoglobulin E (IgE)-mediated allergic diseases. This randomized, double-blind, placebo/active-controlled, single ascending dose Phase 1 study assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH35324 in subjects with atopy. METHODS: Eligible subjects were healthy subjects or atopic adults with mild allergic rhinitis, atopic dermatitis, food allergy, or urticaria, and a serum total IgE level of 30-700 IU/mL (Part A) or > 700 IU/mL (Part B)...
February 20, 2024: International Immunopharmacology
#20
RANDOMIZED CONTROLLED TRIAL
Charlotte G Mortz, Louise Parke, Helene M Rasmussen, Henrik Fomsgaard Kjaer, Carsten Bindslev-Jensen
BACKGROUND: Food allergy is common in childhood with some children having a low threshold and being difficult to protect from accidental ingestion of the offending food. Therapies for this potentially life-threatening condition are highly needed. The aim of this study was to evaluate the efficacy of Omalizumab in food-allergic children. METHODS: This is a single-center, double-blind, placebo-controlled study. Food allergic children with a cumulative threshold ≤443 mg food protein at DBPCFC were randomized to Omalizumab (asthma dose) or placebo (3:1)...
April 2024: Allergy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
